Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury

Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury

Blog Article

Cisplatin is a chemotherapy agent commonly used to treat a wide variety of cancers.Despite the potential for both severe acute and chronic side effects, it remains a preferred therapeutic option for many malignancies due to its potent anti-tumor Body activity.Common cisplatin-associated side-effects include acute kidney injury (AKI) and chronic kidney disease (CKD).These renal injuries may cause delays and potentially cessation of cisplatin therapy and have long-term effects on renal function reserve.Thus, developing mechanism-based interventional strategies that minimize cisplatin-associated kidney injury without reducing efficacy would be of great benefit.

In addition to its action of cross-linking DNA, cisplatin has been shown to affect mitochondrial metabolism, resulting in mitochondrially derived reactive oxygen species (ROS).Increased ROS formation in renal proximal convoluted vibrating-dildos tubule cells is associated with cisplatin-induced AKI and CKD.We review the mechanisms by which cisplatin may induce AKI and CKD and discuss the potential of mitochondrial superoxide dismutase mimetics to prevent platinum-associated nephrotoxicity.